These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 34613592)

  • 1. Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
    Wyatt NJ; Speight RA; Stewart CJ; Kirby JA; Lamb CA
    BioDrugs; 2021 Sep; 35(5):473-503. PubMed ID: 34613592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.
    Lamb CA; O'Byrne S; Keir ME; Butcher EC
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S653-S668. PubMed ID: 29767705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
    Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
    J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-integrin therapy for inflammatory bowel disease.
    Park SC; Jeen YT
    World J Gastroenterol; 2018 May; 24(17):1868-1880. PubMed ID: 29740202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
    Panés J; Salas A
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S633-S640. PubMed ID: 30137311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.
    Pérez-Jeldres T; Tyler CJ; Boyer JD; Karuppuchamy T; Bamias G; Dulai PS; Boland BS; Sandborn WJ; Patel DR; Rivera-Nieves J
    Inflamm Bowel Dis; 2019 Jan; 25(2):270-282. PubMed ID: 30165490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments.
    Rivera-Nieves J
    Curr Opin Gastroenterol; 2015 Nov; 31(6):441-8. PubMed ID: 26398681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules.
    Nakamura K; Honda K; Mizutani T; Akiho H; Harada N
    World J Gastroenterol; 2006 Aug; 12(29):4628-35. PubMed ID: 16937430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
    Danese S; Panés J
    Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.
    Gubatan J; Keyashian K; Rubin SJS; Wang J; Buckman CA; Sinha S
    Clin Exp Gastroenterol; 2021; 14():333-342. PubMed ID: 34466013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions.
    Sands BE
    Dig Dis; 2017; 35(1-2):13-20. PubMed ID: 28147349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease.
    Fiorino G; Correale C; Fries W; Repici A; Malesci A; Danese S
    Expert Rev Clin Immunol; 2010 Jul; 6(4):567-72. PubMed ID: 20594130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
    Van Assche G; Rutgeerts P
    Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.
    Schleier L; Wiendl M; Heidbreder K; Binder MT; Atreya R; Rath T; Becker E; Schulz-Kuhnt A; Stahl A; Schulze LL; Ullrich K; Merz SF; Bornemann L; Gunzer M; Watson AJM; Neufert C; Atreya I; Neurath MF; Zundler S
    Gut; 2020 Feb; 69(2):252-263. PubMed ID: 31092589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of αEβ7 integrin suppresses accumulation of CD8
    Zundler S; Schillinger D; Fischer A; Atreya R; López-Posadas R; Watson A; Neufert C; Atreya I; Neurath MF
    Gut; 2017 Nov; 66(11):1936-1948. PubMed ID: 27543429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.
    Jovani M; Danese S
    Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases.
    Luzentales-Simpson M; Pang YCF; Zhang A; Sousa JA; Sly LM
    Front Cell Dev Biol; 2021; 9():612830. PubMed ID: 33614645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
    Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
    Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.
    Zundler S; Becker E; Schulze LL; Neurath MF
    Gut; 2019 Sep; 68(9):1688-1700. PubMed ID: 31127023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects.
    Mosli MH; Rivera-Nieves J; Feagan BG
    Drugs; 2014 Mar; 74(3):297-311. PubMed ID: 24452878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.